Researches and develops Chinese patent and Western medicines. Manufactures and sells chemical raw materials and biological medicines. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
If every debt were paid off today, $465.4M would still be left in the vault — a solid cushion for hard times.
The market pays 14.3× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
There is $3.6B in the vault; even if every debt were paid off, $465.4M would remain.
It pays out $0.11 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.